ONCOTHERAPY SCIENCE, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 31 JPY | -3.12% |
|
-8.82% | +34.78% |
| Apr. 29 | Poland's Tusk calls prosecutor over potential Orlen scandal | RE |
| Apr. 22 | OncoTherapy Science, Inc. cancelled the transaction announced on April 5, 2024 | CI |
| Sales 2023 | 1.13B 7.02M | Sales 2024 | 610M 3.78M | Capitalization | 4.35B 26.94M |
|---|---|---|---|---|---|
| Net income 2023 | -1.12B -6.92M | Net income 2024 | -1.29B -7.97M | EV / Sales 2023 | 7 x |
| Net cash position 2023 | 1.12B 6.91M | Net cash position 2024 | 527M 3.26M | EV / Sales 2024 | 6.27 x |
| P/E ratio 2023 |
-8.1
x | P/E ratio 2024 |
-3.3
x | Employees | 54 |
| Yield 2023 * |
-
| Yield 2024 |
-
| Free-Float | 84.64% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -3.13% | ||
| 1 week | -8.82% | ||
| Current month | -13.89% | ||
| 1 month | +40.91% | ||
| 3 months | +47.62% | ||
| 6 months | +47.62% | ||
| Current year | +34.78% |
1 week
31.00
37.00
1 month
22.0041.00
Current year
15.0041.00
1 year
15.0041.00
3 years
15.00111.00
5 years
15.00229.00
10 years
15.00736.00
| Managers | Title | Age | Since |
|---|---|---|---|
Junichi Shimada
PSD | President | 63 | 21-11-30 |
Zehyon Paku
CTO | Chief Tech/Sci/R&D Officer | 48 | 17-06-30 |
Yuichi Komine
BRD | Director/Board Member | 52 | 08-05-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Yuichi Komine
BRD | Director/Board Member | 52 | 08-05-31 |
Zehyon Paku
CTO | Chief Tech/Sci/R&D Officer | 48 | 17-06-30 |
Hatsuo Kato
CHM | Chairman | 80 | 20-05-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-07-11 | 31 | -3.12% | 13 057 800 |
| 24-07-10 | 32 | -5.88% | 23,721,300 |
| 24-07-09 | 34 | -5.56% | 10,666,200 |
| 24-07-08 | 36 | 0.00% | 11,709,300 |
| 24-07-05 | 36 | +5.88% | 13,416,900 |
Delayed Quote Japan Exchange, July 11, 2024 at 02:00 am EDT
More quotes
OncoTherapy Science, Inc. is a Japan-based company mainly engaged in the development of drugs. The Company is involved in the development of low molecular drugs, antibody drugs and other drugs, as well as the provision and clinical development of medical candidate substances. The Company operates its business in cooperation with universities and other corporations. The Company provides its licenses to pharmaceutical manufacturers. The Company also involves in T Cell Receptor(TCR) analysis business.
Calendar
2024-08-01
- Q1 2025 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +34.78% | 52.01M | |
| +20.82% | 127B | |
| +21.96% | 116B | |
| +23.64% | 27.69B | |
| -22.97% | 19.62B | |
| -17.03% | 16.26B | |
| -19.03% | 15.49B | |
| +11.66% | 14.81B | |
| -48.41% | 14.39B | |
| +54.78% | 14.11B |
- Stock Market
- Equities
- 4564 Stock
